在与肾脏病相关的贫血中，由于肾脏红细胞生成素不足，炎症和铁缺乏导致红细胞生成被抑制。研究发现低氧诱导因子(hypoxia-inducible factor，HIF)是红细胞生成和铁代谢的关键调节剂，可有效刺激内源性红细胞生成素(plasma erythropoietin，EPO)的产生，降低铁调素水平，调节铁代谢。本综述讨论了HIF对EPO，铁代谢和骨髓造血的调控以及HIF 途径作为肾性贫血治疗的新药物的研究。

In anemia associated with renal disease, erythropoiesis is suppressed due to inadequate erythropoietin(EPO) production in kidney, inflammation and iron deficiency. Studies have found that hypoxia inducible factor (HIF) is a key regulator for erythropoiesis and iron metabolism and an effective stimulant for the production of endogenous erythropoietin, through which ferritin level is reduced and iron metabolism is balanced. This review discusses the regulatory effects of HIF on EPO, iron metabolism and bone marrow hematopoiesis, and also introduces the HIF pathway as a novel target for the treatment of renal anemia.